Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TDG is listed as co-author in patents and patent applications related to the pharmacology and use of (2R,6R)-HNK and other hydroxynorketamines in the treatment of depression and other neuropsychiatric disorders. TDG has served as a consultant for Boehringer Ingelheim during the preceding 3 years but declares no nonfinancial competing interests. SJM has received consultant fees or research support (prior 3 years) from Abbott, Almatica Pharma, Autobahn Therapeutics, Biohaven, BioXcel Therapeutics, Boehringer Ingelheim, Brii Biosciences, Clexio Biosciences, Compass Pathways, Delix Therapeutics, Douglas Pharmaceuticals, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, LivaNova, Merck, Motif Neurotech, Neumora, Neurocrine, Newleos, Perception Neuroscience, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Signant Health, Sunovion Pharmaceuticals, Supernus, and Xenon Pharmaceuticals but declares no nonfinancial competing interests. MF has received research support (preceding 3 years) from AbbVie; Acadia Pharmaceuticals; Aditum Bio Management Company, LLC; Alkermes, Inc.; Allergan; Altimate Health Corporation; Alto Neuroscience, Inc.; Ancora Bio, Inc.; Angelini S.p.A; Aptinyx; Arbor Pharmaceuticals LLC; Axsome; Benckiser Pharmaceuticals, Inc.; Bioclinica, Inc.; Biogen; Biohaven; BioShin Limited; Cambridge Science Corporation; Centrexion Therapeutics Corporation; Cybin IRL Limited; Damona Pharmaceuticals; Eliem Therapeutics LTD; EmbarkNeuro; Genomind, LLC; Gentelon, LLC; Gerbera Therapeutics, Inc.; GH Research Ireland Limited; Happify; Johnson & Johnson; Lundbeck Inc.; Marinus Pharmaceuticals; Medpace, Inc.; Millennium Pharmaceuticals, Inc.; Minerva Neurosciences; NeuraWell Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Novaremed; Otsuka; Peachtree BioResearch Solutions, Inc.; Pfizer; Praxis Precision Medicines; Premier Research International; Protagenic Therapeutics, Inc.; Relmada Therapeutics, Inc.; Shenox Pharmaceuticals; Stanley Medical Research Institute (SMRI); Syndeio Biosciences; Takeda; University of Florida Board of Trustees; University of Michigan; Vistagen; WinSanTor, Inc.; Xenon Pharmaceuticals, Inc.; and XWPharma Ltd. but declares no nonfinancial competing interests. AS is founder of biotech companies Anagin, Inc.; Monument Bio; MindX; and Syndeio Biosciences; scientific advisor and stockholder for Karuna Therapeutics and Aardwolf Therapeutics; and scientific advisor for Artemis Pharmaceuticals but declares no nonfinancial competing interests.
PubMed